Prelude Therapeutics Inc

Prelude Therapeutics Incorporated (Nasdaq: PRLD) is a precision oncology company focused on discovering and developing novel cancer medicines targeting underserved patient populations. The company leverages core competencies in cancer biology and medicinal chemistry to identify compelling biological targets and create new chemical entities that address high unmet medical needs in oncology.

The company's pipeline encompasses multiple therapeutic modalities including kinase inhibitors, targeted protein degraders, and precision antibody drug conjugates. The lead program, PRT12396, is a mutant-selective JAK2V617F inhibitor designed to target myeloproliferative neoplasms by selectively inhibiting the V617F mutation that drives disease in the majority of patients with polycythemia vera, essential thrombocythemia, and myelofibrosis. In November 2025, Prelude entered an exclusive option agreement with Incyte Corporation regarding this program, receiving $60 million upfront with potential for up to $910 million in total payments including milestones and royalties.

The KAT6A selective degrader program represents another key development candidate targeting estrogen receptor-positive breast cancer through selective degradation of the KAT6A protein while sparing the related KAT6B protein to minimize bone marrow toxicity. Additional programs in development include SMARCA2 selective degraders for SMARCA4-deficient cancers and precision antibody drug conjugates with novel degrader payloads developed in collaboration with AbCellera Biologics.

Prelude was founded in 2016 and has achieved multiple FDA investigational new drug clearances. The company does not operate manufacturing facilities and relies on third-party manufacturers for preclinical and clinical drug supply. The company has not yet established commercial infrastructure, planning to pursue commercialization partnerships as appropriate upon regulatory approval.

The company's intellectual property portfolio comprises 282 patents and patent applications globally, including 14 issued U.S. patents. Prelude operates as a clinical-stage biopharmaceutical company competing in the precision oncology space against both large pharmaceutical companies and emerging biotechnology firms focused on targeted cancer therapies.